Lung tumorigenesis suppressing effects of a commercial kava extract and its selected compounds in A/J mice

Thomas E. Johnson, David Hermanson, Lei Wang, Fekadu Kassie, Pramod Upadhyaya, Michael G. O'Sullivan, Stephen S. Hecht, Junxuan Lu, Chengguo Xing

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Lung cancer is the most deadly malignancy in the US. Chemoprevention is potentially a complementary approach to smoking cessation for lung cancer control. Recently, we reported that a commercially available form of kava extract significantly inhibits 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) and benzo(a)pyrene (BaP)-induced lung tumorigenesis in A/J mice at a dose of 10 mg per gram diet. In the present study, we examined the dose-dependent lung tumor inhibitory activities of kava and investigated potential active constituent(s). Mice treated with carcinogen alone contained 12.1±5.8 lung adenomas per mouse 22 weeks after final carcinogen administration. Mice that were fed diets containing kava at dosages of 1.25, 2.5, 5, and 10 mg/g of diet had 8.4±3.5, 6.6±3.5, 4.3±2.4, and 3.8±2.3 lung adenomas per mouse, respectively. This corresponds to a reduction of 31%, 46%, 65% and 69% in tumor multiplicity, which were all statistically significant (p < 0.05). Analyses of lung adenoma tissues derived from kava-treated animals revealed that kava significantly inhibited adenoma cell proliferation while it had no detectable effect on cell death, indicating that kava primarily suppressed lung tumorigenesis in A/J mice via inhibition of cell proliferation. Flavokawains A, B, and C, three chalcone-based components from kava, demonstrated greatly reduced chemopreventive efficacies even at concentrations much higher than their natural abundance, suggesting that they alone were unlikely to be responsible for kava's chemopreventive activity. Kava at all dosages and treatment regimens did not induce detectable adverse effects, particularly with respect to liver. Specifically, kava treatment showed no effect on liver integrity indicator enzymes or liver weight, indicating that kava may be potentially safe for long-term chemopreventive application.

Original languageEnglish (US)
Pages (from-to)727-742
Number of pages16
JournalAmerican Journal of Chinese Medicine
Volume39
Issue number4
DOIs
StatePublished - Jul 11 2011

Fingerprint

Kava
Carcinogenesis
Lung
Adenoma
Diet
Carcinogens
Liver
Lung Neoplasms
Cell Proliferation
Chalcone
Neoplasms
Benzo(a)pyrene
Chemoprevention
Smoking Cessation

All Science Journal Classification (ASJC) codes

  • Complementary and alternative medicine

Cite this

Johnson, T. E., Hermanson, D., Wang, L., Kassie, F., Upadhyaya, P., O'Sullivan, M. G., ... Xing, C. (2011). Lung tumorigenesis suppressing effects of a commercial kava extract and its selected compounds in A/J mice. American Journal of Chinese Medicine, 39(4), 727-742. https://doi.org/10.1142/S0192415X11009202
Johnson, Thomas E. ; Hermanson, David ; Wang, Lei ; Kassie, Fekadu ; Upadhyaya, Pramod ; O'Sullivan, Michael G. ; Hecht, Stephen S. ; Lu, Junxuan ; Xing, Chengguo. / Lung tumorigenesis suppressing effects of a commercial kava extract and its selected compounds in A/J mice. In: American Journal of Chinese Medicine. 2011 ; Vol. 39, No. 4. pp. 727-742.
@article{74a36c5bc01549cca2494a6e3c99b61c,
title = "Lung tumorigenesis suppressing effects of a commercial kava extract and its selected compounds in A/J mice",
abstract = "Lung cancer is the most deadly malignancy in the US. Chemoprevention is potentially a complementary approach to smoking cessation for lung cancer control. Recently, we reported that a commercially available form of kava extract significantly inhibits 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) and benzo(a)pyrene (BaP)-induced lung tumorigenesis in A/J mice at a dose of 10 mg per gram diet. In the present study, we examined the dose-dependent lung tumor inhibitory activities of kava and investigated potential active constituent(s). Mice treated with carcinogen alone contained 12.1±5.8 lung adenomas per mouse 22 weeks after final carcinogen administration. Mice that were fed diets containing kava at dosages of 1.25, 2.5, 5, and 10 mg/g of diet had 8.4±3.5, 6.6±3.5, 4.3±2.4, and 3.8±2.3 lung adenomas per mouse, respectively. This corresponds to a reduction of 31{\%}, 46{\%}, 65{\%} and 69{\%} in tumor multiplicity, which were all statistically significant (p < 0.05). Analyses of lung adenoma tissues derived from kava-treated animals revealed that kava significantly inhibited adenoma cell proliferation while it had no detectable effect on cell death, indicating that kava primarily suppressed lung tumorigenesis in A/J mice via inhibition of cell proliferation. Flavokawains A, B, and C, three chalcone-based components from kava, demonstrated greatly reduced chemopreventive efficacies even at concentrations much higher than their natural abundance, suggesting that they alone were unlikely to be responsible for kava's chemopreventive activity. Kava at all dosages and treatment regimens did not induce detectable adverse effects, particularly with respect to liver. Specifically, kava treatment showed no effect on liver integrity indicator enzymes or liver weight, indicating that kava may be potentially safe for long-term chemopreventive application.",
author = "Johnson, {Thomas E.} and David Hermanson and Lei Wang and Fekadu Kassie and Pramod Upadhyaya and O'Sullivan, {Michael G.} and Hecht, {Stephen S.} and Junxuan Lu and Chengguo Xing",
year = "2011",
month = "7",
day = "11",
doi = "10.1142/S0192415X11009202",
language = "English (US)",
volume = "39",
pages = "727--742",
journal = "American Journal of Chinese Medicine",
issn = "0192-415X",
publisher = "World Scientific Publishing Co. Pte Ltd",
number = "4",

}

Johnson, TE, Hermanson, D, Wang, L, Kassie, F, Upadhyaya, P, O'Sullivan, MG, Hecht, SS, Lu, J & Xing, C 2011, 'Lung tumorigenesis suppressing effects of a commercial kava extract and its selected compounds in A/J mice', American Journal of Chinese Medicine, vol. 39, no. 4, pp. 727-742. https://doi.org/10.1142/S0192415X11009202

Lung tumorigenesis suppressing effects of a commercial kava extract and its selected compounds in A/J mice. / Johnson, Thomas E.; Hermanson, David; Wang, Lei; Kassie, Fekadu; Upadhyaya, Pramod; O'Sullivan, Michael G.; Hecht, Stephen S.; Lu, Junxuan; Xing, Chengguo.

In: American Journal of Chinese Medicine, Vol. 39, No. 4, 11.07.2011, p. 727-742.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Lung tumorigenesis suppressing effects of a commercial kava extract and its selected compounds in A/J mice

AU - Johnson, Thomas E.

AU - Hermanson, David

AU - Wang, Lei

AU - Kassie, Fekadu

AU - Upadhyaya, Pramod

AU - O'Sullivan, Michael G.

AU - Hecht, Stephen S.

AU - Lu, Junxuan

AU - Xing, Chengguo

PY - 2011/7/11

Y1 - 2011/7/11

N2 - Lung cancer is the most deadly malignancy in the US. Chemoprevention is potentially a complementary approach to smoking cessation for lung cancer control. Recently, we reported that a commercially available form of kava extract significantly inhibits 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) and benzo(a)pyrene (BaP)-induced lung tumorigenesis in A/J mice at a dose of 10 mg per gram diet. In the present study, we examined the dose-dependent lung tumor inhibitory activities of kava and investigated potential active constituent(s). Mice treated with carcinogen alone contained 12.1±5.8 lung adenomas per mouse 22 weeks after final carcinogen administration. Mice that were fed diets containing kava at dosages of 1.25, 2.5, 5, and 10 mg/g of diet had 8.4±3.5, 6.6±3.5, 4.3±2.4, and 3.8±2.3 lung adenomas per mouse, respectively. This corresponds to a reduction of 31%, 46%, 65% and 69% in tumor multiplicity, which were all statistically significant (p < 0.05). Analyses of lung adenoma tissues derived from kava-treated animals revealed that kava significantly inhibited adenoma cell proliferation while it had no detectable effect on cell death, indicating that kava primarily suppressed lung tumorigenesis in A/J mice via inhibition of cell proliferation. Flavokawains A, B, and C, three chalcone-based components from kava, demonstrated greatly reduced chemopreventive efficacies even at concentrations much higher than their natural abundance, suggesting that they alone were unlikely to be responsible for kava's chemopreventive activity. Kava at all dosages and treatment regimens did not induce detectable adverse effects, particularly with respect to liver. Specifically, kava treatment showed no effect on liver integrity indicator enzymes or liver weight, indicating that kava may be potentially safe for long-term chemopreventive application.

AB - Lung cancer is the most deadly malignancy in the US. Chemoprevention is potentially a complementary approach to smoking cessation for lung cancer control. Recently, we reported that a commercially available form of kava extract significantly inhibits 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) and benzo(a)pyrene (BaP)-induced lung tumorigenesis in A/J mice at a dose of 10 mg per gram diet. In the present study, we examined the dose-dependent lung tumor inhibitory activities of kava and investigated potential active constituent(s). Mice treated with carcinogen alone contained 12.1±5.8 lung adenomas per mouse 22 weeks after final carcinogen administration. Mice that were fed diets containing kava at dosages of 1.25, 2.5, 5, and 10 mg/g of diet had 8.4±3.5, 6.6±3.5, 4.3±2.4, and 3.8±2.3 lung adenomas per mouse, respectively. This corresponds to a reduction of 31%, 46%, 65% and 69% in tumor multiplicity, which were all statistically significant (p < 0.05). Analyses of lung adenoma tissues derived from kava-treated animals revealed that kava significantly inhibited adenoma cell proliferation while it had no detectable effect on cell death, indicating that kava primarily suppressed lung tumorigenesis in A/J mice via inhibition of cell proliferation. Flavokawains A, B, and C, three chalcone-based components from kava, demonstrated greatly reduced chemopreventive efficacies even at concentrations much higher than their natural abundance, suggesting that they alone were unlikely to be responsible for kava's chemopreventive activity. Kava at all dosages and treatment regimens did not induce detectable adverse effects, particularly with respect to liver. Specifically, kava treatment showed no effect on liver integrity indicator enzymes or liver weight, indicating that kava may be potentially safe for long-term chemopreventive application.

UR - http://www.scopus.com/inward/record.url?scp=79959950118&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79959950118&partnerID=8YFLogxK

U2 - 10.1142/S0192415X11009202

DO - 10.1142/S0192415X11009202

M3 - Article

C2 - 21721153

AN - SCOPUS:79959950118

VL - 39

SP - 727

EP - 742

JO - American Journal of Chinese Medicine

JF - American Journal of Chinese Medicine

SN - 0192-415X

IS - 4

ER -